HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 10680.0
(-2.11%)
KRW 10680.0
(-2.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.3 Billion KRW | 79.72% |
| 2022 | -11.35 Billion KRW | 33.98% |
| 2021 | -17.19 Billion KRW | -1.74% |
| 2020 | -16.9 Billion KRW | -2.92% |
| 2019 | -16.42 Billion KRW | -459.0% |
| 2018 | 4.57 Billion KRW | 194.99% |
| 2017 | -4.81 Billion KRW | 7.4% |
| 2016 | -5.2 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -22.26 Billion KRW | -14056.01% |
| 2024 Q1 | 159.55 Million KRW | 103.82% |
| 2023 FY | -2.3 Billion KRW | 79.72% |
| 2023 Q2 | 3.18 Billion KRW | 361.84% |
| 2023 Q3 | -1 Billion KRW | -131.44% |
| 2023 Q4 | -4.17 Billion KRW | -317.15% |
| 2023 Q1 | -1.21 Billion KRW | 80.86% |
| 2022 Q2 | -1.9 Billion KRW | 3.05% |
| 2022 FY | -11.35 Billion KRW | 33.98% |
| 2022 Q4 | -6.35 Billion KRW | -109.79% |
| 2022 Q3 | -3.03 Billion KRW | -59.08% |
| 2022 Q1 | -1.96 Billion KRW | 69.65% |
| 2021 Q4 | -6.47 Billion KRW | -185.43% |
| 2021 Q3 | -2.26 Billion KRW | 0.0% |
| 2021 FY | -17.19 Billion KRW | -1.74% |
| 2020 FY | -16.9 Billion KRW | -2.92% |
| 2019 FY | -16.42 Billion KRW | -459.0% |
| 2018 FY | 4.57 Billion KRW | 194.99% |
| 2017 FY | -4.81 Billion KRW | 7.4% |
| 2016 FY | -5.2 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 98.782% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 76.255% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 149.289% |
| Bioneer Corporation | -10.58 Billion KRW | 78.255% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | 18.962% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 139.421% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 95.294% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 96.408% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 72.695% |
| Medy-Tox Inc. | 9.75 Billion KRW | 123.6% |
| Peptron, Inc. | -15.92 Billion KRW | 85.541% |
| Amicogen, Inc. | -23.28 Billion KRW | 90.115% |
| Genexine, Inc. | -66.87 Billion KRW | 96.557% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 96.876% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 31.722% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 103.007% |
| SillaJen, Inc. | -20.36 Billion KRW | 88.698% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 116.484% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 87.948% |
| Genomictree Inc. | -8.75 Billion KRW | 73.708% |
| MedPacto, Inc. | -35.32 Billion KRW | 93.483% |
| D&D Pharmatech | 3.93 Billion KRW | 158.522% |
| EASY BIO,Inc. | 15.54 Billion KRW | 114.811% |
| GI Innovation, Inc. | -55.49 Billion KRW | 95.852% |